Gossamer Bio effects 1-for-80 reverse stock split to regain Nasdaq compliance

Gossamer Bio, Inc.

1-for-80 reverse split effective 9/10/2026; split-adjusted trading begins 9/11 under GOSS, new CUSIP 38341P 201.
Authorized common reduced from 4B to 50M shares; total capital stock from 4.07B to 120M.
Convertible note conversion rates (5.00% 2027, 7.50% 2030 notes) and warrant/equity award exercise prices proportionally adjusted.
Intended to regain Nasdaq $1.00 minimum bid price; needs 10 consecutive days by compliance date Oct 5, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.